<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03453320</url>
  </required_header>
  <id_info>
    <org_study_id>RAV</org_study_id>
    <nct_id>NCT03453320</nct_id>
  </id_info>
  <brief_title>Infusion Rate and Volume Kinetics for Hyperoncotic Albumine in Healthy Subjects</brief_title>
  <acronym>(RAV)</acronym>
  <official_title>Infusion Rate and Volume Kinetics for Hyperoncotic Albumine in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Linkoeping</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment with colloidal solutions has during long time been a cornerstone within intensive&#xD;
      care. Lately there has been a shift from synthetic colloids to natural albumine.&#xD;
&#xD;
      One of these solutions is the hyperoncotic &quot;Albumin 20%&quot;. There are however still several&#xD;
      aspects of the physiological effects of hyperoncotic albumin, that are not known.&#xD;
&#xD;
      In this study the main object is to study with what rate hyperoncotic albumin should be&#xD;
      administered. Rapidly 30 minutes or slower 120 minutes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Difference in volume expansion as well as fluid recruitment from the tissues depending on&#xD;
      infusion rate is of interest.&#xD;
&#xD;
      Plasma volume expansion is measured using hemoglobin as a marker and fluid recruitment of&#xD;
      tissue fluid is measured as a combination of plasma volume expansion and urinary output.&#xD;
&#xD;
      Healthy individuals are asked to refrain from eating and drinking the night before the study.&#xD;
      Two hours before study start, the subjects may take a sandwich and a glas to drink.&#xD;
&#xD;
      After 15 minutes of rest baseline blood samples are taken. Subjects are randomised to receive&#xD;
      two rates of albumin solution (Albumin 20%) 3 ml/kg bodyweight at two separate occasions.&#xD;
      Once with an infusion time of 30 minutes, once with an infusion time of 120 minutes. Between&#xD;
      the two infusions there will be an interval of 3 to 20 weeks. Randomization is performed to&#xD;
      chose which rate the subjects start with. 6 in each Group (total 12).&#xD;
&#xD;
      During each occasion15 blood samples are collected, during a 6 hour period. Hemoglobin,&#xD;
      plasma Sodium, colloid osmotic pressure and albumin are analysed. The total volume of blood&#xD;
      collected will be 170 ml at each occasion when an albumin infusion is given.&#xD;
&#xD;
      Urinary output is measured and Urinary Sodium content is measured. Liberal fluid intake is&#xD;
      recommended the same day and the next.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2018</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma volume</measure>
    <time_frame>6 hours</time_frame>
    <description>Albumin infusion expands the plasma volume and dilutes hemoglobin. The dilution of hemoglobin can be measured and is used to calculate the degree of plasma expansion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colloid osmotic pressure</measure>
    <time_frame>6 hours</time_frame>
    <description>Infusion of hyperoncotic albumin increases the colloid osmotic pressure of plasma. Fluid recruitment from the tissues however diminishes the increase of the colloid osmotic pressure. This effect is measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid recruitment from tissues</measure>
    <time_frame>6 hours</time_frame>
    <description>The recruitment of fluid from the tissues due to the increase of colloid osmotic pressure is measured. The total recruitment of fluid from the tissues is the sum of the plasma volume dilution and urinary excretion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Edema Secondary</condition>
  <arm_group>
    <arm_group_label>Rapid - Slow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.&#xD;
First time rapid (30 minutes), second time slow (120 minutes). Albumin solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Slow - Rapid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.&#xD;
First time rapid (120 minutes), second time slow (30 minutes). Albumin solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin solution</intervention_name>
    <description>Infusion rate and effects</description>
    <arm_group_label>Rapid - Slow</arm_group_label>
    <arm_group_label>Slow - Rapid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Healthy, without allergies and with the age 18 years or above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Signs of kidney injury/failure&#xD;
&#xD;
          -  Severe allergies&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Zdolsek, MD, PhD,Assoc prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Linkoeping</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intensive Care Unit, University Hospital</name>
      <address>
        <city>Link√∂ping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 24, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2018</study_first_posted>
  <last_update_submitted>May 25, 2019</last_update_submitted>
  <last_update_submitted_qc>May 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Linkoeping</investigator_affiliation>
    <investigator_full_name>Joachim Zdolsek</investigator_full_name>
    <investigator_title>MD, PhD, Assoc prof, consultant</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

